Claims for Patent: 8,287,847

Summary for Patent: 8,287,847

Title:	Ion binding polymers and uses thereof
Abstract:	The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Inventor(s):	Charmot; Dominique (Campbell, CA), Chang; Han-Ting (Livermore, CA), Liu; Mingjun (Campbell, CA), Klaerner; Gerrit (San Jose, CA)
Assignee:	Relypsa, Inc. (Santa Clara, CA)
Application Number:	12/055,765
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,287,847
Patent Claims:	1. A method for treating hyperkalemia comprising administering a potassium-binding polymer to an animal subject in need thereof wherein the administration is oral, intestinal, or rectal, the potassium-binding polymer being a crosslinked cation exchange polymer comprising acid groups in their acid or salt form, and the crosslinked cation exchange polymer comprising a crosslinked carboxylic polymer having fluoride attached to the carbon atom alpha to the carboxylic acid group. 2. The method of claim 1 wherein the potassium-binding polymer has a swelling ratio of less than 5. 3. The method of claim 1 wherein the potassium-binding polymer has a swelling ratio of less than 3. 4. The method of claim 1 wherein the subject is a human. 5. The method of claim 1 wherein the pharmaceutical composition is administered in the form of a chewable tablet. 6. The method of claim 4 wherein the potassium-binding polymer is administered in a dose of about 0.5 gram/day to about 30 grams/day. 7. The method of claim 1 wherein the ionization of the acid groups is greater than 75% at the physiological pH in the colon. 8. The method of claim 1 wherein the potassium-binding polymer comprises a Ca.sup.2+cationic counterion. 9. A method for treating hyperkalemia comprising administering a potassium-binding polymer to an animal subject in need thereof wherein the administration is oral, intestinal, or rectal, the potassium-binding polymer being a crosslinked alpha-fluoroacrylic acid polymer. 10. The method of claim 9 wherein the alpha-fluoroacrylic acid polymer is crosslinked with divinyl benzene, ethylene bisacrylamide, N,N'- bis(vinylsulfonylacetyl) ethylene diamine, 1,3-bis(vinylsulfonyl) 2-propanol, vinylsulfone, N,N'- methylenebisacrylamide polyvinyl ether, polyallylether, or a combination thereof. 11. The method of claim 9 wherein the alpha-fluoroacrylic acid polymer is crosslinked with divinyl benzene. 12. The method of claim 9 wherein the subject is a human. 13. The method of claim 12 wherein the potassium-binding polymer is administered in a dose of about 0.5 gram/day to about 30 grams/day. 14. The method of claim 9 wherein the ionization of the acid groups is greater than 75% at the physiological pH in the colon. 15. The method of claim 9 wherein the ionization of the acid groups is greater than 75% at the physiological pH in the colon. 16. The method of claim 9 wherein the potassium-binding polymer is in a bead form. 17. A method for treating hyperkalemia comprising administering a potassium-binding polymer to an animal subject in need thereof wherein the administration is oral, intestinal, or rectal, the potassium-binding polymer being a crosslinked alpha-fluoroacrylic acid polymer comprising a Ca.sup.2+cationic counterion. 18. The method of claim 17 wherein the crosslinked alpha-fluoroacrylic acid polymer has a swelling ratio of less than 3. 19. The method of claim 17 wherein the alpha-fluoroacrylic acid polymer is crosslinked with divinyl benzene, ethylene bisacrylamide, N,N'- bis(vinylsulfonylacetyl) ethylene diamine, 1,3-bis(vinylsulfonyl) 2-propanol, vinylsulfone, N,N'-methylenebisacrylamide polyvinyl ether, polyallylether, or a combination thereof. 20. The method of claim 17 wherein the potassium-binding polymer is in a bead form. 21. The method of claim 17 wherein the subject is a human. 22. The method of claim 21 wherein the potassium-binding polymer is administered in a dose of about 0.5 gram/day to about 30 grams/day. 23. The method of claim 17 wherein the ionization of the acid groups is greater than 75% at the physiological pH in the colon. 24. The method of claim 17 wherein the ionization of the acid groups is greater than 75% at the physiological pH in the colon. 25. The method of claim 17 wherein the potassium-binding polymer is in a bead form.